Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07334886 · ClinicalTrials.gov registry record · Phase 1
A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07334886: Completed Phase 1 study, sponsored by Merck Sharp & Dohme.
NCT07334886 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07334886, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The goal of this study is to learn how \[14C\]ulonivirine moves through a healthy person's body over time. Researchers will study how \[14C\]ulonivirine is absorbed by the body, broken down by the body, and how it leaves the body.
Primary Outcome
Urine and fecal samples will be collected to determine the cumulative percentage of radioactivity recovered from both urine and feces.
Interventions
- DRUG [14C]Ulonivirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2025-11-11 |
| Phase | Phase 1 |
What the finished NCT07334886 record still lists
NCT07334886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which [14C]Ulonivirine is the first listed.
NCT07334886 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07334886 about?
NCT07334886 is a clinical study titled "A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)". The goal of this study is to learn how \[14C\]ulonivirine moves through a healthy person's body over time. Researchers will study how \[14C\]ulonivirine is absorbed by the body, broken down by the body, and how it leaves the body.
What is the current status of trial NCT07334886?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-09-17. Estimated completion is 2025-11-11.
What interventions are being tested in trial NCT07334886?
The interventions under investigation include: [14C]Ulonivirine (DRUG).
Who is sponsoring clinical trial NCT07334886?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07334886's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI